Currently full professor at the University of Mons. He previously and successively held the positions of senior scientist at Eli Lilly and toxicologist at Total Petrochemicals. His research is centered on the preclinical development of drugs, in particular the evaluation of risk using the metabolomic approach. He is the author of more than 60 peer-reviewed scientific articles and three book chapters.